Spark's PRV draws luke­warm price, sell­ing for $110M to Jazz

It looks like the go­ing price for pri­or­i­ty re­view vouch­ers is con­tin­u­ing to slide since the go-go days of Ab­b­Vie’s $350 mil­lion pur­chase. Still, this morn­ing’s news that Spark Ther­a­peu­tics is sell­ing its PRV to Jazz Phar­ma­ceu­ti­cals $JAZZ for $110 mil­lion shows the vouch­ers con­tin­ue to draw a pret­ty pen­ny.

Spark $ONCE was award­ed its PRV for rare pe­di­atric dis­ease back when Lux­tur­na was ap­proved, al­low­ing a ther­a­py to nav­i­gate quick­ly through red tape via the in­side track. But Spark is opt­ing to sell off the vouch­er in­stead of us­ing it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER